Board of Directors
Philippa Lewis: Chairperson
Philippa Lewis is a Professional Company Director, Chairperson and Chief Executive with expertise in the Medtech, Biotech, Digital and Artificial Intelligence sectors. Philippa has extensive global, commercial and corporate engagement with demonstrated success. Founding over ten start-ups she has led local and North American IPOs, reverse mergers, complex M&A transactions, strategic capital management and multilateral joint ventures within North America, Europe, China and Australia. She was nominated as Zurich Business Leader of the Year and Telstra Business Woman of the Year and is currently an official company mentor for the Australian Technology Competition as well as an appointed grants assessor for the NSW Government Medtech and Pharma Growth Centre. Philippa is a Graduate of the Australian Institute of Company Directors, The Institute of Public Companies Canada via Simon Fraser University, and The Adelaide University in respect of Legal Arbitration and is a member of the Australian Institute of Company Directors, The MTAA, The Institute of Arbitrators and Mediators and The Resolution Institute.
Dr George Kopsidas: Executive Director and Chief Scientific Officer
Dr Kopsidas is a Founding member of Imunexus and the original developer of the Imunexus technology platform. He is a practiced molecular biologist and biotechnologist with over 17 years experience in protein and antibody engineering (he has engineered 26 potential antibody products). He also has 5 years experience in the field of molecular ageing and mitochondrial diseases where he held a position on the editorial board for the Bio-Gerontology Journal, and well over 10 years experience elucidating the mechanisms of DNA repair. He held academic positions with RMIT and La Trobe Universities and held a Research Fellowship at the National Institutes of Health USA (NIH). He has had senior roles in the commercial sector as the Senior Scientist with the Centre for Molecular Biology and Medicine, the Director of Protein Technologies at Evogenix Ltd, and the Vice-President of Protein Technologies at both Arana Therapeutics and Cephalon Australia. He was the driving force behind the development of the technology platforms of these companies and has a proven track record for developing multiple commercially validated technologies. He was a foundation scientist at Evogenix and the main contributor to the development of their technology platform and product engineering approaches that were later adopted by Arana and Cephalon. He had a major role in the engineering of these company’s R&D pipeline products and continued to develop and expand their technology platforms. He also has a very strong track for developing drugs over multiple projects. He has multiple international publications and patents including joint patents with GSK and Vegenics around antibody therapeutics and has 64 publications and presentations at national and international conferences. He has a strong track record delivering back to investors in previous enterprises including the technical and product development leading to the Evogenix IPO, and the takeover of Evogenix by Peptech to form Arana Therapeutics. Recently he had founded and managed a successful biotechnology consulting company, Melicept, which consulted around protein scaffolds, antibody based therapeutics, biotechnology, protein engineering and molecular biology. He also developed strategic business plans, budgets and resource development and performed due diligence on accessible IP around platforms for novel immunotherapy approaches.
Dr Tim Oldham: Non-Executive Director
Dr Oldham has more than 15 years of life sciences business development, alliance management and sales and marketing experience in Europe, Asia and Australia. He is Executive Leader and Director of Tijan Ventures/Vigilance Health Pty Ltd, providing strategic, commercialisation and company formation advice to the cell and gene therapy sector. He is a former CEO and Managing Director of Cell Therapies Pty Ltd, a leading Asia Pacific provider of manufacturing and distribution services for cell-based therapeutics. He was President of Asia Pacific for Hospira Inc. (2007 to 2012), having held a variety of senior management roles with Mayne Pharma (2002 to 2007) prior to its acquisition by Hospira, working in the field of injectable generics, biosimilars and infusion management systems. Prior to this, Dr Oldham was an engagement manager with McKinsey & Co (1997 to 2001). He is a Non-executive Director of of Acrux Ltd, a listed company developing topical and transdermal generic medicines and has been a Non-Executive Director of Respiri Ltd, a listed medical device and digital health company. Dr Oldham has been chairman of the European Generic Medicines Association’s Biosimilars and Biotechnology Committee, a Director of the Generic Medicines Industry Association, and is a member of AusBiotech’s Regenerative Medicine Advisory Group.
Don has 30 years’ experience as a senior partner of Ernst & Young, Oceania, has extensive experience in IPO’s, transactions and audit. Don has advised and worked with an number of Boards, ranging from some of the largest in Australia to fast growing entrepreneurial and medium sized organisations. Don was the Oceania IPO Leader at Ernst & Young and worked with clients listing on the AUS, US, UK and key Asian stock exchanges. He held positions as Biotech Markets Leader, National Leader of Strategic Growth Markets and on the Board of Partners of Ernst & Young. Don is a Fellow of Chartered Accountants Australia & New Zealand, a member of the Australian Institute of Company Directors.
Christopher Elliot: Chief Financial Officer and Company Secretary
Chris Elliot has 20 years’ experience as a finance and management executive within both chartered accounting and commercial firms, including PricewaterhouseCoopers, APN Outdoor Group Limited (ASX:APO) and Mandoe Media Pty Ltd. Chris is a director of Accension Pty Ltd which is engaged to provide CFO and Company Secretary services to Imunexus. He has extensive experience across the finance, media and digital technology industries, including executive, finance, commercial, business development and operational roles across these industry sectors. Chris is a graduate of the Institute of Chartered Accountants of Australia where he is currently a member.